Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
By Anne-Marie Green, Director of Digital Communications We recently spoke with Burt Rosen, who was diagnosed with both an advanced PNET (Pancreatic Neuroendocrine Tumor) and
This is your opportunity to be part of a global effort to improve neuroendocrine cancer care. The 2nd Survey of Challenges in Access to Diagnostics and Treatment for
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine
By Elyse Gellerman, CEO Representatives from 25 neuroendocrine cancer advocacy groups gathered earlier this month in Sofia, Bulgaria, for the 13th INCA (International Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in
By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others
By Anne-Marie Green, Director of Digital Communications As a 19-year veteran educator, Dr. Barbara Dunham’s learning instincts were set in motion when she was diagnosed
Congress recently passed new tax legislation that will change how charitable contributions are treated starting in 2026. While the bill is complex, we want to